Tocqueville Asset Management L.P. Buys 9,111 Shares of Revvity Inc. $RVTY

Key Points

• Tocqueville Asset Management L.P. increased its stake in Revvity Inc. by 3.9% in Q1, acquiring 9,111 shares to hold a total of 243,736 shares valued at approximately $25.79 million.
• Revvity recently reported Q2 earnings of $1.18 per share, surpassing estimates, with revenues of $720.28 million, indicating a year-over-year revenue growth of 4.1%.
• The company announced a $0.07 quarterly dividend, set to be paid on November 7th, which reflects a modest annual yield of 0.3% and a payout ratio of 11.86%.

Tocqueville Asset Management L.P. grew its stake in shares of Revvity Inc. (NYSE:RVTY - Free Report) by 3.9% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 243,736 shares of the company's stock after purchasing an additional 9,111 shares during the quarter. Tocqueville Asset Management L.P. owned approximately 0.21% of Revvity worth $25,787,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in RVTY. Optiver Holding B.V. purchased a new stake in shares of Revvity during the fourth quarter worth about $33,000. Quarry LP lifted its position in shares of Revvity by 45.7% during the 4th quarter. Quarry LP now owns 303 shares of the company's stock valued at $34,000 after buying an additional 95 shares in the last quarter. Vermillion Wealth Management Inc. acquired a new position in Revvity in the 4th quarter valued at $41,000. New Age Alpha Advisors LLC acquired a new position in Revvity in the 1st quarter valued at $44,000. Finally, Continuum Advisory LLC raised its holdings in shares of Revvity by 39.3% during the 4th quarter. Continuum Advisory LLC now owns 471 shares of the company's stock worth $53,000 after acquiring an additional 133 shares during the period. 86.65% of the stock is currently owned by institutional investors.

Revvity Stock Performance

RVTY traded down $1.0760 on Thursday, hitting $90.6240. The company's stock had a trading volume of 202,238 shares, compared to its average volume of 1,177,892. The company's 50 day simple moving average is $94.69 and its 200-day simple moving average is $99.49. The company has a quick ratio of 2.75, a current ratio of 3.33 and a debt-to-equity ratio of 0.43. Revvity Inc. has a 12 month low of $85.12 and a 12 month high of $129.50. The firm has a market cap of $10.52 billion, a P/E ratio of 38.45, a price-to-earnings-growth ratio of 2.45 and a beta of 0.91.

Revvity (NYSE:RVTY - Get Free Report) last posted its quarterly earnings data on Monday, July 28th. The company reported $1.18 earnings per share for the quarter, beating the consensus estimate of $1.14 by $0.04. The firm had revenue of $720.28 million for the quarter, compared to analysts' expectations of $711.26 million. Revvity had a net margin of 10.19% and a return on equity of 7.66%. The business's quarterly revenue was up 4.1% on a year-over-year basis. During the same quarter last year, the company posted $1.22 EPS. Revvity has set its FY 2025 guidance at 4.850-4.950 EPS. Analysts forecast that Revvity Inc. will post 4.94 EPS for the current year.

Revvity Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, November 7th. Investors of record on Friday, October 17th will be paid a dividend of $0.07 per share. The ex-dividend date of this dividend is Friday, October 17th. This represents a $0.28 annualized dividend and a yield of 0.3%. Revvity's payout ratio is presently 11.86%.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. The Goldman Sachs Group decreased their price objective on Revvity from $140.00 to $125.00 and set a "buy" rating for the company in a research note on Tuesday, April 29th. Robert W. Baird cut their price target on Revvity from $127.00 to $125.00 and set an "outperform" rating on the stock in a research report on Tuesday, April 29th. Raymond James Financial reaffirmed an "outperform" rating and set a $115.00 price objective (down previously from $120.00) on shares of Revvity in a report on Tuesday, July 29th. Wall Street Zen lowered Revvity from a "buy" rating to a "hold" rating in a report on Sunday, August 3rd. Finally, JPMorgan Chase & Co. lowered their target price on Revvity from $120.00 to $100.00 and set a "neutral" rating on the stock in a report on Tuesday, April 29th. Ten analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $120.07.

Revvity Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.